HK1043809B - 對抗乳頭瘤病毒感染及腫瘤的藥物成份 - Google Patents

對抗乳頭瘤病毒感染及腫瘤的藥物成份 Download PDF

Info

Publication number
HK1043809B
HK1043809B HK02103266.9A HK02103266A HK1043809B HK 1043809 B HK1043809 B HK 1043809B HK 02103266 A HK02103266 A HK 02103266A HK 1043809 B HK1043809 B HK 1043809B
Authority
HK
Hong Kong
Prior art keywords
papillomavirus
pharmaceutical composition
polypeptide
composition according
derived
Prior art date
Application number
HK02103266.9A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1043809A1 (en
Inventor
Balloul Jean-Marc
Bizouarne Nadine
Paule Kieny Marie
Original Assignee
Transgene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1043809(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene S.A. filed Critical Transgene S.A.
Publication of HK1043809A1 publication Critical patent/HK1043809A1/xx
Publication of HK1043809B publication Critical patent/HK1043809B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02103266.9A 1996-07-30 2002-04-30 對抗乳頭瘤病毒感染及腫瘤的藥物成份 HK1043809B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (2)

Publication Number Publication Date
HK1043809A1 HK1043809A1 (en) 2002-09-27
HK1043809B true HK1043809B (zh) 2004-12-03

Family

ID=9494633

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103266.9A HK1043809B (zh) 1996-07-30 2002-04-30 對抗乳頭瘤病毒感染及腫瘤的藥物成份

Country Status (12)

Country Link
EP (2) EP0862634B2 (enExample)
JP (2) JP4070815B2 (enExample)
AT (2) ATE265535T1 (enExample)
AU (1) AU736720B2 (enExample)
CA (1) CA2234263C (enExample)
DE (2) DE69728914T2 (enExample)
DK (2) DK1149910T3 (enExample)
ES (2) ES2215805T3 (enExample)
FR (1) FR2751879B1 (enExample)
HK (1) HK1043809B (enExample)
PT (2) PT1149910E (enExample)
WO (1) WO1998004705A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble in ICAM-1 as a biomarker for predicting therapeutic response
DK2411815T3 (en) 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
MX2012000979A (es) 2009-07-21 2012-06-08 Transgene Sa Composición enzimática para la digestión de embriones de pollo.
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX378901B (es) 2014-12-01 2025-03-10 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
IE910909A1 (en) † 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK1298211T3 (da) * 1991-07-19 2006-11-13 Univ Queensland Polynukleotidsegment af HPV16-genom
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
EP0789774A2 (en) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
DE69706825T2 (de) 2002-05-02
DE69706825D1 (de) 2001-10-25
EP0862634B2 (fr) 2006-03-01
PT862634E (pt) 2002-03-28
ES2215805T3 (es) 2004-10-16
DE69706825T3 (de) 2006-08-24
ATE205881T1 (de) 2001-10-15
AU736720B2 (en) 2001-08-02
ES2163795T3 (es) 2002-02-01
DE69728914T2 (de) 2005-04-07
AU3855297A (en) 1998-02-20
DK0862634T3 (da) 2002-01-21
CA2234263A1 (fr) 1998-02-05
FR2751879A1 (fr) 1998-02-06
PT1149910E (pt) 2004-09-30
DE69728914D1 (de) 2004-06-03
CA2234263C (fr) 2009-10-13
EP1149910B1 (fr) 2004-04-28
DK1149910T3 (da) 2004-08-02
DK0862634T4 (da) 2006-05-08
FR2751879B1 (fr) 1998-10-30
WO1998004705A1 (fr) 1998-02-05
ATE265535T1 (de) 2004-05-15
JP2000500662A (ja) 2000-01-25
JP4198735B2 (ja) 2008-12-17
JP2007254474A (ja) 2007-10-04
JP4070815B2 (ja) 2008-04-02
HK1043809A1 (en) 2002-09-27
ES2163795T5 (es) 2006-07-16
EP0862634B1 (fr) 2001-09-19
EP0862634A1 (fr) 1998-09-09
EP1149910A1 (fr) 2001-10-31

Similar Documents

Publication Publication Date Title
JP4198735B2 (ja) パピローマウイルス腫瘍および感染を治療するための医薬組成物
US7670607B2 (en) Pharmaceutical compositions for treating papillomavirus tumors and infection
JP4489288B2 (ja) 細胞における局在性が改変された免疫ポリペプチドに基づく抗腫瘍組成物
KR100240183B1 (ko) 인간 유두종 비루스 단백질을 암호화하는 재조합 비루스 벡터
JP2926270B2 (ja) 乳頭腫ウイルス誘発腫瘍の予防及び治療のための薬理組成物
BRPI0806350A2 (pt) uso de uma molécula de ácido nucléico, uso de um vetor, uso de um particula viral infecciosa, vetores, particula viral infecciosa e composição
JP7053491B2 (ja) 治療用ｈｐｖワクチン組み合わせ
US20050118139A1 (en) Vaccine using papilloma virus e proteins delivered by viral vector
AU781653B2 (en) Pharmaceutical composition for treating papollomavirus tumour and infection

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160729